ESR1 and cancer: In contrast mutations in TP53 are more prevalent in the claudin-low group, although the difference did not reach statistical significance and their prevalence (15.8%) is lower than in both basal and claudin-low ER-negative/HER2-negative cancers (86.9% and 29.8%, respectively, Table 4 and Table 8).